January 7th, 2025 – Bioforum, The Data Masters, a leading global clinical research organization (CRO) specializing in biometric services and solutions, today announced the formation of its inaugural Board of Directors. This milestone marks a pivotal step in Bioforum’s continued commitment to innovation, operational excellence, and global expansion.

Joining the newly established board are Bryan Katz and Calvin Liou, seasoned leaders with extensive experience in clinical research, healthcare strategy, and operational leadership.

“Establishing a Board of Directors reflects Bioforum’s growth and the need for strong strategic guidance as we advance our mission to deliver exceptional biometric solutions for the clinical trials industry,” said Amir Malka, CEO and Co-Founder of Bioforum. “Bryan and Calvin bring deep industry knowledge, proven leadership, and unique perspectives that will undoubtedly support Bioforum’s continued success and expansion.”

Bryan Katz is a senior Pharma Life Science industry advisor and CEO of PharmaStreet Research.   He is particularly focused on deal strategy, innovation and enabling technologies within the pharmaceutical services and clinical research space. Bryan was most recently the Chief Strategy Officer at ProPharma and previously held leadership roles at Syneos Health, KCR, IQVIA, PwC and Abbott Laboratories.  His insights will strengthen Bioforum’s growth strategy, industry partnering and go-to-market efforts. 

Calvin Liou, an accomplished healthcare investor, adds expertise in scaling organizations and fostering growth. He brings current and prior Board experience with both growth and mature-stage healthcare companies, having spent a decade previously as an investment banker and private equity professional.  He started Olive Tree GP, a healthcare and technology-focused merchant bank after leaving TA Associates as a Senior Vice President in 2024. 

The formation of the Board of Directors comes as Bioforum continues to enhance its comprehensive suite of biometric services, including data management, biostatistics, statistical programming, and medical writing. Leveraging proprietary technology solutions such as BioGrid (visual analytics), JetConvert (SDTM conversion), and Validify (risk analysis and validation), Bioforum remains committed to helping its clients accelerate clinical development with high-quality, reliable data.

“I’m honored to join the Board of Directors and contribute to Bioforum’s continued growth and leadership in the biometrics space,” said Katz. Liou added, “Bioforum’s commitment to innovation and excellence makes it a standout partner for clinical research organizations worldwide. I look forward to supporting its ambitious vision.”